Skip to content

Clinical observation of Qiruiweishu capsule combined with conventional western medicine in the treatment of chronic gastritis with erosion

Clinical observation of Qiruiweishu capsule combined with Rabeprazole in the treatment of chronic gastritis with erosion

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070080
Enrollment
Unknown
Registered
2023-03-31
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic gastritis

Interventions

control group:On the basis of basic treatment, the patients were given rabeprazole sodium enteric-coated tablets (Jichuan Pharmaceutical Group Co., Ltd., GYZZ H20040916, specification: 10mg/tablet), 1
If accompanied by Helicobacter pylori infection, the patient should be treated with quadruple antibiotic (Rabeprazole 10mg bid, amoxicillin potassium clavulanic acid 5 pills bid, clarithromycin 0.5 bi
Treatment group:On the basis of basic treatment, the patient was given Qiruiweishu capsule, 4 capsules at a time, twice a day
Rabeprazole sodium enteric-coated tablets (Jichuan Pharmaceutical Group Co., Ltd., GYZZ H20040916, specification: 10mg/tablet), 10mg/time, twice a day. Take it continuously for 28 days. In the same wa

Sponsors

Jiangsu Second Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: It conforms to the TCM syndrome differentiation standard of CEG stomach collateral stasis syndrome. Conforming to the western medicine diagnostic standard of CEG. The age is 18-65 years old. There was no history of taking PPI, bismuth and antibiotics within 1 month before enrollment. The patients and their families agreed to participate in the clinical trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: It does not meet the criteria of syndrome differentiation and diagnosis of Chinese and Western medicine. Gastrointestinal ulcer, bleeding, tumor and atrophic gastritis. Severe cardiopulmonary insufficiency, or serious systemic disease. Allergic constitution or allergy to the drugs used in this subject. Pregnant or lactating women.Legally recognized as disabled patients, including deaf, blind, dumb, mentally handicapped, and have drug addiction or alcohol dependence.Participants who have also participated in other clinical trials or have participated in studies that may affect the results of this study.

Design outcomes

Primary

MeasureTime frame
Gastroscope effect;

Secondary

MeasureTime frame
TCM syndrome score;Hp eradication rate;

Countries

China

Contacts

Public ContactLiang Zheng

Jiangsu Second Hospital of Traditional Chinese Medicine

1254604363@qq.com13915919898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026